Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ACADEMIA
ACADEMIA
- Pfizer, Merck KGaA Set to Leverage Complementary Tie-Up to Develop PD-L1 Inhibitor
June 2, 2015
- Opdivo Shows OS Rate of 62% in HCC at 12 Months: ASCO
June 1, 2015
- MHLW-Funded Study Calls for Use-Based Development Plans for Combination Drugs
May 7, 2015
- Six Deaths Confirmed through Tofacitinib PMS, Guidelines Not Followed in All Cases
April 30, 2015
- Biometric Society of Japan to Establish Certification System for Biostatisticians
April 17, 2015
- Study Group Recommends “Reference Groups,” Dose-Escalation Studies to Promote Development of Ultra-Orphan Drugs
April 8, 2015
- Medical University Association to Strengthen Collaboration with Industry
April 3, 2015
- Stop Use of SGLT-2 Inhibitors, NSAIDs in Elderly: Japan Geriatrics Society
April 3, 2015
- CRPC Drugs Xtandi, Zytiga Neck-and-Neck in Key Opinion Leader Poll
April 1, 2015
- New Stroke Guidelines to “Strongly Recommend” NOACs for NVAF
March 31, 2015
- Keytruda Demonstrates Superior OS, PFS to Yervoy in Advanced Melanoma in PIII Study: Merck
March 30, 2015
- Univ. of Tokyo to Provide Access to Comprehensive Database of Drug and Medical Device Seeds Starting in April
March 26, 2015
- Drug-Use Result Surveys Should Be Conducted in Elaborate Manner: Dr Narukawa
March 25, 2015
- Yervoy Extends Survival of Terminal Melanoma Patients, Same Might Hold True for Other Immunotherapies: Prof.
March 19, 2015
- Researcher Has High Hopes for Immunotherapies as Fourth Pillar of Cancer Treatment
March 17, 2015
- Large-Scale Genomic Screening Project Gets Underway to Make Gene Database of 4,500 Cancer Patients
March 12, 2015
- Urological Cancer Society to Be Inaugurated in October
March 12, 2015
- Interview on SGLT-2 Inhibitor Use (2): Prof. Watada Calls for Caution in Analyzing EPPV Data
March 9, 2015
- Interview on SGLT-2 Inhibitor Use (1): Prof. Ueki Says Flat Sales Reflect Cautious Prescribing by Physicians
March 6, 2015
- Astellas, Nagasaki Univ. Extend Joint Research Deal for Dengue Fever by 1 Year
March 3, 2015
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…